All In Biotech

Drug Trial Radar · NCT03146416

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Evinacumab in Healthy Japanese and Caucasian Subjects

Last checked: Nov 20, 2026Latest source record: Jun 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Actual

Start

May 16, 2017

Primary completion

Jun 14, 2018

Study completion Jun 14, 2018

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
May 10, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to compare the safety and tolerability of subcutaneous (SC) and intravenous (IV) doses of evinacumab in healthy Japanese and Caucasian subjects.

Conditions

  • Healthy Volunteers

Interventions

  • EvinacumabDrug

    SC or IV administration of Evinacumab

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline up to week 31
  2. Severity of TEAEsTime frame: Baseline up to week 31

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • WCCT Global, Inc.

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.